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ABSTRACT
Multiple myeloma (MM) is a clinically and genetically heterogeneous plasma cell 
(PC) malignancy. Whole-exome sequencing has identified therapeutically targetable 
mutations such as those in the mitogen-activated protein kinase (MAPK) pathway, 
which are the most prevalent MM mutations. We used deep sequencing to screen 
167 representative patients with PC dyscrasias [132 with MM, 24 with primary PC 
leukemia (pPCL) and 11 with secondary PC leukemia (sPCL)] for mutations in BRAF, 
NRAS and KRAS, which were respectively found in 12%, 23.9% and 29.3% of cases. 
Overall, the MAPK pathway was affected in 57.5% of the patients (63.6% of those 
with sPCL, 59.8% of those with MM, and 41.7% of those with pPCL). The majority 
of BRAF variants were comparably expressed at transcript level. Additionally, gene 
expression profiling indicated the MAPK pathway is activated in mutated patients. 
Finally, we found that vemurafenib inhibition of BRAF activation in mutated U266 cells 
affected the expression of genes known to be associated with MM. Our data confirm 
and extend previous published evidence that MAPK pathway activation is recurrent in 
myeloma; the finding that it is mediated by BRAF mutations in a significant fraction 
of patients has potentially immediate clinical implications.
INTRODUCTION
Multiple myeloma (MM) is a malignant disorder 
characterized by the clonal proliferation of bone marrow 
(BM) plasma cells (PCs). The genetic background and 
clinical course of the disease are highly heterogeneous, 
ranging from pre-malignant monoclonal gammopathy 
of undetermined significance to smoldering MM, 
symptomatic MM, and extra-medullary MM/plasma 
cell leukemia (PCL) [1]. Clinically, PCL has two forms: 
primary PCL (pPCL) originating de novo, or secondary 
PCL (sPCL) arising from a pre-existing MM [2]. Recent 
therapeutic advances have extended overall patient 
survival, but current anti-MM treatments are not specific 
and act by means of pleiotropic mechanisms. However, 
genome-wide next-generation sequencing (NGS) studies 
have provided a rationale for molecularly aimed treatment 
approaches by identifying specifically targetable mutations 
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such as those in the mitogen-activated protein kinase 
(MAPK) pathway, which are the most prevalent mutations 
in MM [3-6]. Along with already known NRAS and KRAS 
mutations, these also include BRAF mutations, which have 
been recently reported to occur in 4-15% of patients [4-
6] and may be of potentially immediate clinical relevance 
because of the availability of effective BRAF inhibitors 
that are also being investigated in MM treatment [7-9].
In this study, we used targeted NGS to screen a large 
and representative series of patients with intra- and extra-
medullary MM (including pPCL or sPCL) for mutations 
in BRAF, NRAS and KRAS. We evaluated the relationships 
between the identified variants and the clinical and 
biological features of the disease, and determined the 
transcriptional signature associated with MAPK pathway 
activation in MM.
RESULTS
BRAF mutations in PC dyscrasias
In order to estimate the frequency of BRAF 
mutations in different forms of PC dyscrasias, 167 
specimens (132 MM, 24 pPCLs and 11 sPCLs) and 21 
HMCLs underwent NGS of the mutational hot-spots, 
namely exons 11 and 15 (Cosmic Release v70, at http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/). The 
median depth of coverage was 233x (range 100-962x) and, 
after the exclusion of intronic, synonymous and germline 
variants, nine distinct single nucleotide variations (SNVs) 
were detected in 20 patients and one HMCL. All of the 
mutations were missense substitutions (Table 1) and their 
occurrence was confirmed in an independent PCR product 
in all cases. Variant allele frequencies (VAFs) ranged from 
0.86% to 70.7% of total reads per sample (Supplementary 
Figure 1).
Mutations were detected in 10.6% of the patients 
with MM at onset (14/132), 20.8% of pPCLs (5/24) and 
9.1% of sPCLs (1/11). The main molecular features of the 
20 BRAF-mutated patients are shown in Supplementary 
Table 1A; there was no significant association with any 
molecular lesion (Supplementary Table 1B). Five of these 
patients (four with MM and one with pPCL) carried a 
mutation whose VAF was below the Sanger detection limit 
(i.e. about 10% under our experimental conditions). The 
only mutation among the HMCLs was found in the U266 
cell line, which harbored the K601N substitution in 65% 
of the sequencing reads, as previously reported [4-6].
The variants mainly targeted exon 15 (17/20, 85%) 
(Figure 1). The most frequent mutation was V600E (found 
in seven cases), which was reported to destabilize the 
hydrophobic interaction between the glycine-rich loop 
and the activation segment, thus locking the protein in 
its active conformation and increasing BRAF kinase 
activity [10, 11]. The same occurs in the case of the 
high activity mutant G469A [11] (found in three cases), 
whereas activation of the MEK–ERK signalling pathway 
by E586K (detected in one sample) could be mediated by 
the disruption of an intra-molecular regulatory interaction 
[12]. The G596R substitution (found in one case) impairs 
the kinase activity of BRAF, which cannot activate MEK 
directly but is still capable of activating MEK–ERK 
signalling by forming heterodimers with CRAF (which 
is activated in a RAS-independent manner), and also 
increases the activation of MEK–ERK signalling [12]. 
The K601 residue was targeted by two different mutations, 
K601N (in U266 cells) and K601T (in MM-039); to the 
best of our knowledge, no functional characterization of 
these mutants is available, although it has been shown that 
another substitution in this position (K601E) increases 
BRAF kinase activity [11]. The variants at D594 (the most 
frequently mutated residue in our patients, with D594N 
in four cases, D594G in three, and D594E in one) are 
more puzzling as they have been described as inactivating 
BRAF, making it unable to phosphorylate MEK, activate 
CRAF, or stimulate cell signalling. Interestingly, these 
variants are the third most common BRAF mutations in 
cancer (Cosmic Release v70), and often co-exist with 
RAS mutations [13], which otherwise generally occur in a 
mutually exclusive manner.
In order to assess whether the identified mutations 
were actually expressed, we sequenced those of our 
BRAF-mutated patients for whom mRNA material was 
available. Notably, the NGS results indicated that the 
Table 1: Summary of non-synonymous BRAF variants identified by NGS
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Figure 1: Compendium of the BRAF mutations in primary MM/PCL patients as found in the present series and other 
recent reports [4-6, 24]. The three regions conserved in all RAF proteins (conserved region (CR) 1, CR2 and CR3) are shown beneath 
the main figure, with the activation segment within CR3 indicated by diagonal lines. Exons are numbered under the boxes.
Figure 2: BRAF mutations detected on genomic DNA and cDNA. A. Percentages  of  variant  BRAF sequencing  reads  identified 
by  NGS  analyses  of  genomic  DNA  and  retrotranscribed total RNA. B. Correlation between VAFs detected on genomic DNA and 
cDNA.
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Table 2: Mutation status of BRAF, NRAS and KRAS genes in 19 sequentially analyzed patients
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VAFs detected in genomic DNA and retro-transcribed 
RNA were significantly linearly correlated (Figure 2).
NRAS and KRAS mutations
In order to obtain a more complete picture of MEK-
ERK signalling activation in MM, we also investigated 
the entire dataset for mutations in NRAS and KRAS, two 
GTPases that are known for long time to be involved in 
myelomagenesis [4, 6, 14, 15].
Sequencing of the mutation hot-spots of NRAS 
(exons 2 and 3) and KRAS (exons 2, 3 and 4) revealed the 
occurrence of mutations in respectively 23.9% (40/167) 
and 29.3% of the cases (49/167). As a whole, NRAS and 
KRAS mutations were detected in 55.3% of MM cases, 
20.8% of pPCL, and 54.5% of sPCL.
In particular, NRAS mutations were found in 26.5% 
of the MMs at onset, 4.2% of the pPCLs, and 36.4% of 
the sPCLs (P = 0.008) (Supplementary Table 2A), whose 
main molecular features are shown in Supplementary 
Table 2B. In line with previous studies (particularly in 
MM), virtually all of the identified mutations affected hot-
spot codons 61 (36/50, 72%), 13 (5/50, 10%) and 12 (3/50, 
6.5%).
KRAS mutations were detected in 32.6% of the MMs 
at onset, 16.7% of the pPCLs, and 18.2% of the sPCLs; 
the most frequently targeted residues were Gly12 and 
Gln61, followed by Gly13 and other codons in exons 2, 3, 
and 4, each mutated in one or two cases (Supplementary 
Table 3A). The frequency of mutational substitution for 
a particular amino acid at these codons was absolutely 
consistent with previous observations in MM [4, 6].
The NRAS mutations showed only a weak negative 
association with MAF/MAFB translocations (P = 0.0775) 
(Supplementary Table 2C), and chromosome 17p 
deletions were less frequent in KRAS-mutated samples (P 
= 0.0019) (Supplementary Table 3B-C). The latter were 
also characterized by more frequent hyperdiploidy (P = 
0.0124), although this association disappeared when the 
analysis was restricted to the MM samples alone (data 
not shown), probably because of the low prevalence of 
hyperdiploidy in the PCL samples.
Considering on the whole the three analyzed genes, 
the MEK/ERK signalling pathway was affected by 
mutational events in more than half of the cases (96/167, 
57.5%) (Figure 3), being more frequent in sPCL (7/11, 
63.6%) and MM (79/132, 59.8%), and relatively less 
frequent in pPCL (10/24, 41.7%); this latter finding is 
consistent with what newly emerged from a WES study 
in a smaller fraction of the pPCL patients of the present 
series [16]. Confirming recent data indicating multiple 
mutations within the same pathway [4, 6], we identified 
13 samples with concomitant mutations in two genes 
(Figure 3): three cases in BRAF and NRAS, five in BRAF 
and KRAS, and five in NRAS and KRAS. In all patients, the 
co-existing mutations had different VAFs, thus supporting 
the occurrence of tumor subclones. Notably, five of the 
eight BRAF variants in D594 that are predicted to cause 
BRAF inactivation [13] co-existed with a NRAS or KRAS 
mutation.
Next, based on VAF, sample purity, and, if available, 
DNA copy number at BRAF, NRAS or KRAS genomic 
loci, we estimated the expected fraction of MM cells 
harboring each identified mutation. We then compared 
it with the percentage of CD138 positive-cells carrying 
main cytogenetic alterations (such as IGH translocations, 
hyperdiploidy, deletion of chromosome 13 or 1p, or 1q 
gain) as assessed by fluorescence in situ hybridization 
(data not shown). In such a way, we found that one of 
the following scenarios (observed at quite comparable 
frequencies in our series) occurred in most of the cases: 
(i) the same fraction of cells (corresponding to the whole 
tumor clone or to a part thereof) was affected both 
by mutations and other chromosomal lesions, or (ii) 
mutations occurred in a subclone of MM cells harboring 
other alterations. In line with recent WES studies, these 
data indicate that, although involving driver genes, MAPK 
mutations can be clonal (compatible with early events) in 
some patients or subclonal (compatible with late events) 
in others [4, 6], and may occur at variable times during 
tumor evolution compared to the other molecular lesions.
Sequential analysis of BRAF, NRAS and KRAS 
mutations
In order to gain further insights into the longitudinal 
status of BRAF/NRAS/KRAS mutations, we analyzed 
specimens taken from 19 patients at two different times: 
14 with MM and two with pPCL at onset and relapse; 
two with MM at onset and at the time of leukemic 
transformation; and one at early and relapsed leukemic 
phase (Table 2 and Figure 4). The second specimens 
in each case were collected after at least one line of 
treatment with various regimens. In six cases (MM-239, 
Figure 3: Heat map distribution of MAPK pathway gene mutations among MM/PCL patients. The rows correspond to the 
indicated genes, and columns represent individual MM or PCL samples, which are colour-coded on the basis of gene status (white: wild-
type; light red: Sanger-undetectable mutations; dark red: Sanger-detectable mutations).
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MM-263, MM-271, MM-282, MM-286, and MM-281), 
all three genes were wild-type at both timepoints. Four 
of the remaining patients had one mutated gene (BRAF 
in PCL-026, NRAS in MM-334, and KRAS in PCL-038 
and MM-442) at a quite constant load throughout disease 
course. Others showed the appearance or disappearance of 
NRAS and KRAS variants with low VAFs (the occurrence 
of KRAS G12A and G12R in MM-340; the occurrence 
of KRAS Q61L in MM-200, which also retained KRAS 
Q61H at a quite constant VAF; the loss of KRAS G12S in 
MM-004; the loss of KRAS G13D in MM-151, which also 
stably carried KRAS Q61H; the loss of NRAS Q61K in 
MM-327, which also harbored the KRAS Q61H mutation 
in about 40% of the sequencing reads at both timepoints). 
A reduction in the mutational load of a fully clonal variant 
(KRAS Q22K, with an allele frequency of 50% at MM 
onset and 31% at relapse) was found in one case (MM-
280). Interestingly, the disappearance of a high frequency 
mutation was associated in all cases with the occurrence/
clonal expansion of a further mutation in another gene of 
the pathway (the loss of KRAS G12D in MM-429, which 
acquired the NRAS Q61R mutation; and the loss of KRAS 
G12V in MM-146, which showed a concurrent increase 
in the allele frequency of NRAS Q61H from 8% to 41%). 
Notably, the leukemic transformation in MM-295 was 
accompanied by a dramatic increase in the VAF of NRAS 
G12D (9% to 100%), whereas the mutation burden of the 
co-existing BRAF D594N variant remained stable at about 
50%.
Transcriptomic profiles of patients with BRAF/
NRAS/KRAS mutations
In order to identify the transcriptional profiles 
related to BRAF, NRAS and KRAS mutations in primary 
tumors, we used microarray technology to investigate 
a large number (n = 142) of the samples analyzed by 
NGS. Assuming that alterations in a limited number of 
myeloma cells do not appreciably affect gene expression, 
we arbitrarily chose a lower VAF cut-off value of 20% 
for the supervised analysis of 60 wild-type and 68 
mutated patients. They differentially expressed 86 
genes (18 of which emerged at the highest stringency 
level) (Supplementary Table 4A): 27 up- and 59 down-
regulated in the mutated cases. Interestingly, functional 
enrichment analysis revealed the involvement of a 
statistically significant fraction of modulated transcripts 
in MAPK signalling (PRKD2, SPRED2, MAPKAPK2, 
CD300A, ARL6IP5, DUSP6, PPM1L, GRB2, LAMTOR3, 
SPRED1, LYN, EDN1, RASGRP1 and ACVR1B) at both 
biological process (GO:0000165, q-value=3.29E-03) and 
pathway level (198779 WikiPathway, q-value=1.33E-02) 
(Supplementary Table 4B).
Principal component analysis (PCA) based on the 
expression of the 18 most statistically significant genes 
allowed a good separation between mutated and wild-type 
patients, without any apparent gene-specific discrimination 
(Figure 5). Notably, a few tumors not affected by mutations 
in any of the three genes (but possibly mutated in other 
genes of the pathway) showed the same activated MAPK 
Figure 4: Changes of BRAF, NRAS and KRAS 
mutational burden during disease progression. Allele 
frequencies of each variant are plotted at both time points for 
patients found mutated at diagnosis and/or relapse. The VAFs of 
mutations co-occurring in an individual patient are identified by 
the same color.
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pathway transcriptional profile as the mutated cases, as it 
has been found in other cancers [17]; conversely, some 
mutated samples had a wild-type-like expression profile, 
including 10 cases carrying mutations with a low VAF; 
MM-295 (BRAF D594N); and PCL-026, harboring both 
D594N and E586K BRAF mutations. Interestingly, NGS 
analysis of PCL-026 indicated that both variants were 
carried on the same allele, thus suggesting that the putative 
abrogation of BRAF negative regulation generated by 
the E586K substitution may not lead to increased BRAF 
signalling because of the concomitant occurrence of the 
D594N mutation.
Molecular pathways dependent on BRAF-
mediated signalling in MM
In order to elucidate the transcriptional programmes 
related to BRAF activation in MM, we used vemurafenib 
(a BRAF inhibitor that has recently proved to be a 
promising anti-myeloma drug in clinical settings) [7] 
to inhibit BRAF activity in U266 cells which carry the 
K601N mutation and showing constitutive activation of 
MEK/ERK signalling (Supplementary Figure 2D). After 
confirming its ability to suppress the MAPK pathway 
and impair the proliferation of cultured U266 cells 
(Supplementary Figure 2A-2D), we compared the gene 
expression profiles of U266 cells treated with vemurafenib 
(30 μM) or DMSO for 12 hours. Gene set enrichment 
analysis (GSEA) was used to identify a priori defined sets 
of genes showing concordant modulation between treated 
and control phenotypes; in particular, the analysis ranked 
the genes on the basis of their differential expression 
between the classes (Supplementary Table 5A and B 
lists the 150 genes showing the highest up- and down-
regulation following treatment) and identified a number 
of gene sets whose members tended to occur among genes 
with the largest differential expression between treated 
and control U266 cells (Supplementary Table 6A-B). 
The gene sets coordinately down-regulated in response 
to the drug included those associated with the gene 
ontology biological process of inactivating MAP kinase 
activity (Supplementary Figure 3A-3B) and mitosis (in 
line with the reduction of cell growth revealed by the cell 
viability analysis) (Figure 6A-6B). We also found other 
significantly down-regulated gene sets in the treated cells 
that are consistent with MEK-ERK pathway inhibition, 
including genes up-regulated in NIH3T3 cells transformed 
by activated KRAS [18]; genes down-regulated in the 
ANBL-6 MM cell line after IL-6 withdrawal [19] 
(Figure 6C-6D) (also in line with the drug-induced 
down-regulation of IL-6 in U266 cells) (Supplementary 
Figure 5: Multidimensional scaling plot using the most significant genes (n = 18) differentially expressed between 
BRAF/NRAS/KRAS-mutated and wild-type patients. Each point represents a single sample and is coloured on its type (patient/
normal control) and mutation status as measured by sequence analysis. In the case of co-existing mutations of which only one had an allele 
frequency of >20%, the color corresponds to the gene with the highest mutational load.
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Figure 6: Enrichment plots and heat maps of selected gene sets detected by GSEA in U266 treated with vemurafenib 
in comparison with DMSO controls. A., C. The green curves show the enrichment score and reflect the degree to which each gene 
(black vertical lines) is represented at the bottom of the ranked gene list. Normalized enrichment score (NES) and FDRs are shown for each 
gene set; the gene sets with an FDR of <0.05 were considered enriched. B., D. Heat maps of the genes constituting the leading edge subsets 
within the gene sets shown in panels A and C, respectively, in treated and control U266 cells..
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Table 5B); genes up-regulated in the proliferation (PR) 
subgroup of multiple myeloma described by Zhan et al 
[20] (Supplementary Figure 3C-3D); genes regulated by 
retinoblastoma via the E2F family of transcription factors; 
and genes identified in ovarian cancer downstream of 
CDKN1A and TP53 [21], which of note was up-regulated 
in the vemurafenib-treated U266 cells (Supplementary 
Table 5A). The gene sets that positively correlated with 
the treated phenotype (i.e. they were hyper-expressed 
following treatment) included those found up-regulated 
in MM1.S cells treated with the tyrosine kinase inhibitor 
adaphostin [22] (Supplementary Figure 4A-4B), and 
in response to the Ras-inhibitor salirasib in a panel of 
cancer cell lines with constitutively active HRAS [23] 
(Supplementary Figure 4C-4D).
DISCUSSION
Members of the MAPK signalling pathway, such as 
NRAS, KRAS and BRAF are among the most frequently 
mutated proto-oncogenes in cancer. Notably, activating 
alterations of the BRAF serine/threonine kinase gene have 
also been recently described in whole-genome and exome 
sequencing (WGS/WES) studies of MM further extending 
the evidence of a widespread dysregulation of MAPK 
signalling in the disease [4-6, 24]. Over the last few years, 
BRAF has received considerable attention as a result of 
the success of targeted malignant melanoma therapy 
[25], and encouraging preliminary results have emerged 
from exploratory studies of the use of BRAF inhibitors in 
patients with BRAF-mutated MM [7, 9].
To the best of our knowledge, ours is the first study 
to use NGS to assess BRAF, NRAS and KRAS mutations in 
a large cohort of patients with MM (including primary and 
secondary leukemic forms) in the context of other clinical 
and biological features of the disease, and to determine 
a MAPK mutation-associated transcriptional signature in 
MM.
BRAF mutations were identified in 12% of the 
study population. Their frequency in our series of patients 
with MM at onset (10.6%) was more consistent with that 
found in WGS/WES studies [4, 6] than that found in other 
studies [7, 26]. Our NGS analysis identified mutations 
with a low VAF and a number of variants other than the 
classic V600E, the most common variant in melanoma and 
a hallmark of hairy cell leukemia. Published functional 
data indicate that most BRAF mutational events are 
responsible for the activation of MEK-ERK pathway, 
which is also caused by alterations in NRAS or KRAS 
(whose involvement in disease pathogenesis has already 
been extensively proven) [15, 26, 27] in an even more 
substantial percentage of patients.
We detected genetic alterations in ERK signalling 
in 57% of our patients, thus confirming the crucial role 
this pathway plays in MM development. In line with 
the findings of the most recent sequencing studies [4, 
6], our analysis revealed concomitant substitutions in 
more than one of the investigated genes in 13 patients, 
although their simultaneous occurrence at high VAF was 
rare. Interestingly, the concomitant occurrence of five of 
the eight D594BRAF variants with mutations in KRAS or 
NRAS may be explained by the experimentally described 
synergy of kinase-dead BRAF mutations involving D594 
and oncogenic RAS. Their cooperation in inducing tumor 
progression, indeed, has been demonstrated in a murine 
model of melanoma [13], thus confirming the hypothesis 
that the high frequency of this inactivating mutation (also 
observed in our MM patient cohort) is incompatible with 
a random event.
Furthermore, serial analyses of BRAF, N- and K-RAS 
mutations during disease progression revealed a slightly 
more complex scenario than that found by Bolli et al. [4], 
who described either clonal variants at both timepoints 
or the presence of acquired/increased variants in the 
later sample, in line with the expected positive selection 
of mutated subclones. Besides these patterns, we also 
observed the disappearance of variants with relatively high 
VAF values, but always occurring concurrently with the 
emergence/clonal expansion of an additional mutation in 
another gene of the pathway.
The activation of the MEK-ERK pathway as a 
result of BRAF and RAS mutations identified by NGS 
was confirmed by the GEP data of the same patients, 
indicating that the MAPK cascade is one of the most 
enriched biological processes involving genes that are 
differentially expressed between mutated and wild-type 
patients. Together with the detection of the majority of 
BRAF genomic variants at cDNA level, this highlights 
the particular importance of alterations in this pathway in 
terms of both occurrence and phenotypical impact in the 
context of the heterogeneous mutational pattern of MM. 
A recent RNA-seq analysis of a subset of patients who 
had previously undergone WES, indeed, has shown that 
most of the identified mutations occur in genes whose 
expression is very low or undetectable [28]; in addition, 
the mutation frequencies at genomic and transcriptional 
levels were found not comparable for many genes [28]. 
As far as our study is concerned, we observed that 
genomic and transcriptional VAFs of BRAF were highly 
concordant in mutated patients. This new finding further 
strengthens the rationale for BRAF-targeted therapeutic 
strategies. Furthermore, gene expression analysis of 
vemurafenib-treated BRAF mutated U266 cells revealed 
that the blockade of BRAF activation was accompanied 
by changes in the expression levels of critical genes 
for myeloma cells, such as TP53, or IL-6 and MM 
proliferation-associated genes [20] (respectively up- and 
down-regulated following treatment). These data are 
consistent with the findings from preclinical studies of 
MEK inhibitors, showing the inhibition of myeloma cell 
proliferation and the abrogation of paracrine signals for 
MM cell survival within the bone marrow niche, thus 
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blocking osteoclast differentiation and reducing myeloma-
induced angiogenesis [29-32].
The clinical relevance of BRAF and NRAS/KRAS 
mutations is still unclear. Bolli et al. found no significant 
survival difference between cases with and without KRAS, 
NRAS or BRAF mutations [4], whereas Andrulis et al. [7] 
found that overall survival was significantly shorter in 
their MM patients carrying BRAF V600E. We were able 
to evaluate the impact of KRAS, NRAS or BRAF mutations 
in terms of progression-free survival, overall survival and 
response rates in our prospective series of pPCL patients 
followed up for 2.8 months but found no significant 
associations (data not shown). However, this was a small 
series and, as pPCL is a high-risk clinical entity with a 
complex pattern of genetic aberrations, it was not entirely 
suitable for such an assessment.
In conclusion, our data extend previous evidence 
that MEK-ERK pathway activation is very common 
in myeloma. The finding that it is the result of BRAF 
mutations in a significant percentage of patients has 
potentially immediate clinical implications. A few 
instances of the therapeutic use of the BRAF inhibitor 
vemurafenib in MM have been reported [7, 9], and it is 
to be hoped that more precise indications concerning its 
efficacy will emerge from the ongoing phase II Basket 
study (NCT01524978) of vemurafenib in patients with 
BRAF V600E mutation-positive cancers, which also 
includes MM patients [33]. However, the paradoxically 
tumor-enhancing effects of BRAF inhibitors in the 
case of sub-clonal BRAF or co-existent BRAF and RAS 
mutations indicate the need for the accurate molecular 
characterization of patients in order to obtain the most 
from targeted therapeutic strategies.
MATERIALS AND METHODS
Patients and cell lines
After the patients had given their informed consent 
in accordance with institutional guidelines (clearance 
from Ethic Committee, Fondazione Ospedale Maggiore di 
Milano), pathological BM specimens were obtained during 
standard diagnostic procedures from 132 patients with 
newly diagnosed MM, 24 cases of pPCL at onset and 11 
cases of sPCL (79 males; median age 66 years, range 42-
85), admitted from July 2001 to April 2014. MM and PCL 
were diagnosed based on the previously described criteria 
[2, 34]. One hundred patients had an immunoglobulin 
(Ig-)G protein monoclonal component; 34 IgA; one IgG/
IgA; and one IgM protein; 101 cases had the light chain κ; 
63 λ; two λ+κ. Twenty-five MM cases were in stage IA, 
58 IIA/B and 49 IIIA/B, according to Durie and Salmon 
criteria [35]. Many of these patients have been described 
in previous papers [36, 37], and 16 of the 24 pPCL patients 
were participants in a multicentre clinical trial (RV-PCL-
PI-350, EudraCT No. 2008-003246-28) [38].
The human myeloma cell lines (HMCLs) used in 
the study were NCI-H929, OPM2, JJN3, KMS-12, KMS-
28, KMS-34, KMS-18, KMS-11, KMS-26, AMO1, RPMI 
8226, delta-47, SK-MM-1, UTMC-2, MM.1S, U266, 
MM1-144, CMA-03 and CMA-03/06, LP-1, and KMS-
27, all of which have been previously reported by us [39, 
40] except for delta-47, UTMC-2, MM.1S and MM1-144 
(kindly provided by Dr. G.Tonon - San Raffaele Scientific 
Institute, Milan).
Sample preparation and molecular analyses
The BM specimens were collected from patients at 
the time of diagnosis; 19 cases were re-sampled at relapse/
MM leukemic transformation after a median of 30 months. 
The PCs were purified (≥90% in all cases) using CD138 
immunomagnetic microbeads as previously described [41, 
42]. The main genomic aberrations (IGH translocations, 
hyperdiploidy, del(13q), del(17p), and 1q gain) were 
characterized by fluorescence in situ hybridization (FISH) 
in all cases as previously described [43] (Supplementary 
Table 7).
Mutation analyses
NGS of the BRAF (exons 11 and 15), NRAS (exons 
2 and 3) and KRAS (exons 2-4) mutation hotspots was 
performed from genomic DNA on the Genome Sequencer 
Junior instrument (Roche-454 Life Sciences, Penzberg, 
Germany) as previously described [44]. Details concerning 
the primer sequences and sequencing protocol are 
available in the Supplementary Methods. The sequencing 
reads were mapped to the reference sequence (RefSeq 
NG_007873.2 for BRAF, NG_007572.1 for NRAS, and 
NG_007524.1 for KRAS) and analyzed by means of 
Amplicon Variant Analyzer software (Roche).
The presence of non-synonymous variants was 
verified in an independent PCR product by means of 
conventional sequencing whenever the sensitivity of 
Sanger’s method was consistent with variant allele 
frequency (VAF), or by means of an additional ultra-deep 
pyrosequencing run (median depth of coverage=1 402x) 
in the case of variants with a low VAF. In order to exclude 
germline variants, we sequenced the matched normal DNA 
when available, or consulted the Human dbSNP Database 
at NCBI (Build 142) (http://www.ncbi.nlm.nih.gov/snp). 
The occurrence of BRAF variants was also verified at 
transcriptional level (Supplementary Methods).
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Gene expression profiling and data analysis
The samples for gene expression profiling (GEP) 
were profiled using the GeneChip Human Gene 1.0 ST 
array (Affymetrix, Santa Clara, CA, USA) as previously 
described [37] (Supplementary Methods). Supervised 
analyses of the patient dataset were made using the 
Significant Analysis of Microarrays (SAM) software 
[45]. The list of differentially expressed genes was 
submitted to the ToppGene Suite portal (http://toppgene.
cchmc.org) for functional enrichment analysis using the 
ToppFun application [46]. For GEP of BRAF inhibitor-
treated or untreated U266 cells (two independent replicas 
for each condition), microarray data were globally 
analyzed by Gene Set Enrichment Analysis (GSEA) [47]. 
Details concerning GEP data generation are given in the 
Supplementary Methods.
The principal component analysis (PCA) of the 
samples was performed by singular value decomposition 
of the considered data expression matrix using the 
prcomp function in the stats package, and the results were 
visualized using the plot3d function in the rgl package for 
R software.
The GEP data have been deposited in the NCBI 
Gene Expression Omnibus database (GEO; http//www.
ncbi.nlm.nih.gov/geo; accession No. GSE66293).
Statistical analysis
All of the contingency analyses were made using 
two-sided Fisher’s exact test (P value < 0.05).
Cell-based assays
The U266 cell line was maintained in RPMI 
1640 medium supplemented with 10% fetal calf serum. 
Vemurafenib (Sigma-Aldrich, Saint Louis, MO, USA) was 
dissolved in dimethyl sulfoxide (DMSO) stock solutions 
and stored at -20°C before being added to log-phase 
cells at 30 μM on the basis of the findings of previous 
experiments testing dose-dependent cell proliferation and 
survival (data not shown), which confirmed the cells’ very 
weak sensitivity to the drug [48]. Standard procedures 
were used to assess the number and viability of the treated 
and control cells, and analyze the cell cycle and apoptosis 
(Supplementary Methods).
Western blot analysis
Total cell extracts underwent standard SDS-PAGE 
and Western blotting procedures (see Supplementary 
Methods for antibody description).
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